Article Text
EBM Verdict
General medicine
Lorcaserin in obesity: minimal benefits and ill-defined harms
Statistics from Altmetric.com
Footnotes
Contributors IJO and JKA both contributed equally to the text.
Competing interests IJO and JKA are coauthors of a previously published systematic review and meta-analysis that assessed the benefits and harms of centrally acting antiobesity medicines. IJO holds grant funding from the NIHR School of Primary Care Research (NIHR Evidence Synthesis working group Project No 390).
Patient consent Not required.
Provenance and peer review Not commissioned; internally peer reviewed.